<DOC>
	<DOCNO>NCT02066389</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-group , placebo control , multicenter study assess safety efficacy ABT-494 subject active rheumatoid arthritis fail Methotrexate alone .</brief_summary>
	<brief_title>A Study Investigating Efficacy Safety ABT-494 Given With Methotrexate ( MTX ) Subjects With Rheumatoid Arthritis Who Have Had Inadequate Response MTX Alone</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Diagnosed RA base either 1987revised ACR classification criterion 2010 American College Rheumatology ( ACR ) /European League Rheumatism ( EULAR ) criteria ≥ 3 month . 2 . Have active RA define follow minimum disease activity criterion : ≥ 6 swollen joint ( base 66 joint count ) Screening Baseline Visits . ≥ 6 tender joint ( base 68 joint count ) Screening Baseline Visits . hsCRP &gt; Upper Limit Normal ( ULN ) OR positive rheumatoid factor antiCyclic Citrullinated Peptide ( CCP ) Screening . 3 . Subjects must receive oral parenteral methotrexate therapy ≥ 3 month stable prescription 7.5 25 mg/week least 4 week prior Baseline Visit . Subjects also stable dose folic acid ( equivalent ) least 4 week prior Baseline Visit . Subjects continue stable dos methotrexate folic acid throughout study . 4 . Except MTX , subject must discontinue oral DiseaseModifying AntiRheumatic drug ( DMARDs ) prior Baseline Visit specify least five time mean terminal elimination halflife drug , whichever longer : ≥ 4 week prior Baseline Visit minocycline , penicillamine , sulfasalazine , hydroxychloroquine , chloroquine , azathioprine , gold formulation , cyclophosphamide ≥ 8 week prior Baseline Visit leflunomide elimination procedure follow , adhere washout procedure ( i.e. , 11 day washout colestyramine , 30 day washout activated charcoal ) 5 . Subject negative Tuberculosis ( TB ) Screening Assessment . If subject evidence latent TB infection , subject must initiate complete minimum 2 week ( per local guideline , whichever long ) ongoing TB prophylaxis document completion full course TB prophylaxis , prior Baseline Visit . 6 . Subjects take nonsteroidal antiinflammatory drug ( NSAIDS ) , acetaminophen , oral corticosteroid ( equivalent prednisone ≤ 10 mg ) , inhaled corticosteroid stable dose least 4 week prior Baseline Visit stable medical condition keep stable dose throughout study . NSAIDs , acetaminophen tramadol , codeine , hydrocodone propoxyphene take need allow may take 24 hour prior study visit . Oral inhale corticosteroid take PRN allow may take 24 hour prior study visit . 7 . Subjects must discontinue high potency opiate include ( limited ) : oxycodone , oxymorphone , fentanyl , levorphanol , buprenorphine , methadone , hydromorphone , morphine least 4 week prior Baseline Visit . 1 . Female pregnant breastfeeding . 2 . Prior exposure Janus Activated Kinase ( JAK ) inhibitor ( e.g. , tofacitinib , baricitinib ) . 3 . Prior exposure investigational approve biologic RA therapy . 4 . Receipt investigational drug chemical biologic nature within minimum 30 day 5 halflives drug ( whichever longer ) prior Week 0 Visit . 5 . Current expect need immunosuppressant medication , except methotrexate . Use oral intake &gt; 10 mg prednisone/day equivalent corticosteroid therapy ( see inclusion criterion 7 ) . 6 . Subject treat intraarticular parenteral administration corticosteroid precede 8 week prior Week 0 Visit . 7 . Screening laboratory value meet follow criterion : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 1.5 × ULN Estimated glomerular filtration rate ( eGRF ) simplify 4variable Modification Diet Renal Disease ( MDRD ) formula &lt; 40 mL/min/1.73 m2 Total white blood cell count ( WBC ) &lt; 3,000/µL Absolute neutrophil count ( ANC ) &lt; 1,200/µL Platelet count &lt; 100,000/µL Absolute lymphocyte count &lt; 750/ µL Hemoglobin &lt; 9 gm/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>anti-inflammatory agent</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>antirheumatic agent</keyword>
</DOC>